Cardiff Oncology Inc. (NASDAQ: CRDF) announced positive results from its phase 2 clinical trial evaluating onvansertib in combination with standard ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE